Global Healthcare Investment and Financing Report – January 2025: 194 Deals, $8.004 Billion Raised

According to incomplete statistics from Arterial Intelligence, in January 2025, there were a total of 194 financing events in the global healthcare sector (excluding IPOs, private placements...Including additional issuance, etc.), disclosed a total financing amount of approximately USD 80.04 billion (approximately RMB 578.77 billion). Among them, there were 63 financing events in the Chinese market.Disclosed total financing amount is approximately 956 million US dollars; Overseas markets witnessed 131 financing events with a disclosed total financing amount of approximately 7.048 billion US dollars.。

From the perspective of transaction amount, number of financing events, and focus on emerging fields, the investment and financing situation of the global healthcare industry in December 2024 is analyzed.In January 2025, the global medical and health industry's investment and financing scale showed an overall upward trend, with the total amount increasing by approximately 100.51% month-over-month, and the number of events rising month-over-month as well.Increase by approximately 24.36%。

In terms of large-scale financing events, there were 26 deals exceeding $100 million this month, with a cumulative financing amount of $4.389 billion. Among them, 25 occurred in overseas regions and one took place in China. These 26 companies are: new drug developer Verdiva Bio, medical data platform provider Truveta, cardiovascular drug developer Kardigan, healthcare data service provider Innovaccer, medical screening and disease prevention service provider Neko, drug development and manufacturing company Aviceda Therapeutics, clinical-stage drug developer Windward Bio, small molecule drug developer Tenvie Therapeutics, epigenetic editing technology developer Tune Therapeutics, clinical contract research organization Caidya, home healthcare service provider Cera, medical diagnostic technology researcher Patho Care, healthcare large language model (LLM) provider Hippocratic AI, renal patient care provider Evergreen Nephrology, immune reset therapy developer Ouro Medicines, medical remote monitoring device developer FIRE1, insulin delivery device developer CeQur, biotechnology developer Aspect Biosystems, intelligent robot developer Shanghai Fourier Intelligence Co., Ltd., diagnostic service provider Neuberg Diagnostics, care operations software provider Qventus, non-invasive gastrointestinal-related diagnostic product developer Geneoscopy, intelligent drug development platform and new drug developer Insilico Medicine, biopharmaceutical contract research service provider Aragen, cancer treatment drug developer Umoja Biopharma, and chronic pain treatment device developer Saluda Medical.

In terms of global healthcare industry sub-sector financing, compared to medical devices and consumables, digital health, medical services, and pharmaceutical commerce, the total amount and number of financing events in biopharmaceuticals dominated in January, accounting for 48.65% and 35.57% of the entire field, respectively.

Notably, Verdiva Bio, a developer of new drugs for metabolic diseases, completed a $411 million Series A financing round, securing the top spot in this month’s funding. Verdiva Bio Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic diseases. Verdiva Bio's most advanced therapy is VRB-101, an oral GLP-1 peptide currently in clinical development. It demonstrated first-in-class efficacy potential in a Phase 1 study conducted in Australia and confirmed the feasibility of once-weekly dosing. The company is also developing a range of islet amyloid polypeptide molecules, including oral and subcutaneous agonists, as well as other undisclosed programs that have the potential to enhance efficacy, improve tolerability, and achieve healthier weight loss outcomes.

On January 23, 2025, Neko Health, a provider of medical screening and disease prevention services, raised $260 million in Series B funding from investors including Lightspeed Venture Partners, General Catalyst, OG Venture Partners, Rosello, Lakestar, and Atomico. This latest funding will drive Neko Health's expansion plans, enabling the company to open new locations: increasing access to Neko Body Scan in existing and new regions; enhancing technology: further developing its AI-driven platform and scanning capabilities; and growing its team: expanding the workforce to support its rapid growth.

On January 14, 2025, Aragen, a provider of preclinical contract research and development services, announced that it had received a $100 million investment from Quadria Capital, a private equity fund focused on healthcare in Asia. This funding will support Aragen's strategic expansion of its capabilities and infrastructure, enabling the company to meet the growing demand for outsourced services from innovators in the United States and Europe.

Cancer Treatment Drug Developer Umoja Biopharma Completes $100 Million Series C Financing, Aiming for New Heights in Cell Therapy

On January 14, 2025, Umoja Biopharma, a developer of cancer treatment drugs, successfully completed its $100 million Series C financing round. The round was co-led by Double Point Ventures and DCVC Bio, with participation from both new and existing investors, including ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, and the University of Minnesota Endowment. The $100 million raised in this financing round will be utilized by Umoja Biopharma for several key areas to fully propel the company to new heights.

On January 13, 2025, Qventus, a provider of nursing operations software, secured $105 million in funding led by KKR, with participation from Bessemer Venture Partners, Northwestern Medicine, HonorHealth, and Allina Health. This funding accelerates the company’s ability to deliver AI-based automation and AI operational assistants across more care settings, building on the success of its existing products, such as Qventus’ surgical growth and inpatient capacity solutions, as well as new solutions developed based on the capabilities of its first-to-market AI operational assistant platform.

On January 13, 2025, Truveta, a medical data platform provider, completed a $320 million financing round, invested by Regeneron and Illumina. The company claims that the funds will be used for the Truveta Genomics Initiative, which aims to compile genetic data from tens of millions of consenting and de-identified volunteers to create "the largest and most diverse database of genotype and phenotype information ever."。

Global Full-Service Clinical Contract Research Organization (CRO) Caidya Announces $165 Million Strategic Growth Financing

On January 13, 2025, Caidya, a global full-service clinical contract research organization (CRO), announced the completion of a $165 million strategic growth investment from funds managed by Rubicon Founders. The investment from Rubicon Founders will support Caidya's next phase of growth, enabling continued organic expansion and exploration of strategic acquisitions.。

Cardiovascular Drug Developer Kardigan Raises $300 Million in Series A Financing to Develop New Heart Disease Medications

On January 13, 2025, cardiovascular drug developer Kardigan secured $300 million in Series A funding on January 10, led by Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. The funds will be used to advance Kardigan's focus on the most unmet needs in cardiology, starting with disease opportunities and patient populations that are resistant or poorly managed by current therapies, including primary and secondary cardiomyopathies that lead to heart failure.

Gene Editing Company Tune Therapeutics Completes Over $175 Million Series B Financing to Advance Leading Epigenome Editing Programs

On January 13, 2025, gene editing company Tune Therapeutics completed a Series B financing round of over $175 million, led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation. This funding will accelerate the development of the company's existing pipeline, currently centered on Tune-401, its clinical-stage epigenetic silencing drug for chronic hepatitis B (HBV). It will also support the development of other gene, cell, and regenerative therapy projects already underway at Tune and advance its broader mission of applying the power and versatility of epigenetic therapies to common and chronic diseases.

Cera, a home healthcare service provider, secures $150 million in debt financing to alleviate pressure on the NHS through an AI-powered healthcare platform

On January 13, 2025, Cera, a provider of home healthcare services, secured $150 million in debt financing led by BDT & MSD Partners and Schroders Capital. Key investors included Earlymarket, Guinness Ventures, DigitalHealth, and Robin Klein. The new funding will support several initiatives: expanding its AI-driven platform to predict health deterioration, enhancing technical capabilities, broadening specialized care services (nursing, physical therapy, mental health support, and clinical trials), improving AI skills for healthcare workers, and pursuing overseas opportunities—building on its recent entry into the German market.

Clinical-Stage Drug Developer Windward Bio Secures $200 Million in Series A Financing

On January 13, 2025, clinical-stage drug developer Windward Bio secured $200 million in Series A financing, co-led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities, with participation from SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The funds will accelerate the clinical progress of programs aimed at improving outcomes for patients with advanced immune disorders, initially focusing on severe respiratory conditions.

Neuberg Diagnostics Secures INR 9.4 Billion from Kotak Alt, Marking the Largest-Ever Primary Fundraise in India’s Diagnostic Industry

On January 11, 2025, Neuberg Diagnostics, a diagnostic service provider, received 9.4 billion rupees in funding from Kotak Alt on January 10, with 3 Capital serving as the exclusive financial advisor. This funding will enable Neuberg Diagnostics to enhance its capabilities in personalized medicine and integrated diagnostics, and expand its footprint inorganically across China.

Chronic Pain Treatment Device Developer Saluda Medical Completes $100 Million Financing to Support Its Novel Closed-Loop Dose-Controlled Neuromodulation Platform

On January 10, 2025, Saluda Medical, a developer of chronic pain treatment devices, completed a $100 million financing round led by Redmile Group. Other existing investors, including Wellington Management, TPG Life Sciences Innovation, Fidelity Management & Research Company, Action Potential Venture Capital, and funds and accounts advised by T. Rowe Price Associates, also participated. New investor Piper Heartland Healthcare Capital joined this round as well. Saluda Medical plans to use the proceeds to advance the commercialization of its Evoke neuromodulation system. Evoke is the first commercial application of the company's proprietary neuromodulation platform.。

Ouro Medicines, a Researcher of Immune Reset Therapy, Secures $120 Million in Series A Funding, Defining the Future of Treatment for Patients with Immune-Mediated Diseases

On January 10, 2025, Ouro Medicines, a research company specializing in immune reset therapies, secured $120 million in Series A funding. The round was co-led by TPG Life Sciences Innovation, NEA, and Norwest Venture Partners, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other undisclosed investors. Ouro Medicines is an immune reset company that directly addresses chronic immune-mediated diseases by combining scientific expertise, a proven track record of advancing cell depletion therapies through clinical trials, and a robust pipeline.

Healthcare Large Language Model (LLM) Provider Hippocratic AI Secures $141 Million in Series B Funding, Led by Kleiner Perkins

On January 9, 2025, Hippocratic AI, a provider of large language models (LLM) for healthcare, secured $141 million in Series B funding. The round was led by Kleiner Perkins, with participation from A16z, General Catalyst, Premji, NVIDIA, SV Angel, Universal Health Services (UHS), and WellSpan Health. Hippocratic AI has developed a safety-focused large language model (LLM) for healthcare.

Clinical-Stage Cardiometabolic Company Verdiva Bio Secures $411 Million Series A Financing to Advance Next-Generation Therapies

On January 9, 2025, clinical-stage cardiometabolic company Verdiva Bio Limited closed an oversubscribed $411 million Series A financing round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. The Series A proceeds will be used to advance the clinical development of Verdiva Bio's existing assets and expand its industry-leading cardiometabolic portfolio.

Biotech Company Aspect Biosystems Completes $115 Million Series B Financing to Develop Bioprinted Tissue Therapies

On January 9, 2025, biotechnology company Aspect Biosystems announced on January 8 that it had completed a $115 million Series B financing round. This round was led by Dimension, with participation from existing and new investors, including Novo Nordisk, Radical Ventures, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: a Breakthrough T1D Venture. Additionally, the funds will drive the expansion of Aspect's industry-leading full-stack tissue therapy platform, which integrates proprietary AI bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials.。

Healthcare Data Service Provider Innovaccer Secures $275 Million in Series F Funding to Expand Its Healthcare Intelligence Cloud

On January 9, 2025, healthcare data service provider Innovaccer secured $275 million in Series F funding, led by B Capital Group, Banner Health, Danaher Ventures LLC, Generation Investment Management, Kaiser Permanente, and M12. This investment will drive Innovaccer's efforts to expand collaborations with existing clients, introduce new AI and cloud functionalities, and grow the developer ecosystem on its platform. The company plans to add multiple co-pilots and agents to its product suite, including utilization management, prior authorization, clinical decision support, clinical documentation, care management, and contact centers.

Non-invasive gastrointestinal diagnostic product developer Geneoscopy completes $105 million Series C financing to power next-generation gastrointestinal diagnostics testing

On January 8, 2025, Geneoscopy, Inc., a developer of non-invasive gastrointestinal-related diagnostic products, completed a $105 million Series C financing round. The round was led by Bio-Rad Laboratories, with participation from Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management, Mercy Health, and Tri Locum Partners. This funding enables the company to achieve key milestones, including the launch and commercialization of Geneoscopy's at-home, stool-based colorectal cancer screening test, ColoSense. The funds will also allow the company to continue investing in its innovative pipeline for inflammatory bowel disease diagnostic tests to address unmet critical medical needs.

Raised Over 100 Million USD, Insilico Medicine’s China Tech Headquarters to Settle in Pudong

On January 8, 2025, the signing ceremony for the Pudong-Hong Kong Joint Leading Investment in Insilico Medicine's financing agreement was held in Pudong on November 6. This is reported to be the first case of equity investment in biopharmaceutical enterprises under the "Pudong-Hong Kong Joint Leading Investment." The investors in this round of financing include: Value Partners Group, Pudong Venture Capital, Puxing Synergy Fund, Xiyi Venture Capital; existing investors such as Warburg Pincus continued to follow up, with an expected total scale exceeding 100 million US dollars. Insilico Medicine stated that it plans to use the funds raised in this round for the optimization of artificial intelligence models and algorithms, upgrading and construction of automated robotic laboratories, further clinical validation of the leading anti-idiopathic pulmonary fibrosis drug ISM001-055, and efficient advancement and continuous exploration of other self-developed or collaborative drug R&D pipelines.

Shanghai Fourier Intelligence Co., Ltd. Announces Completion of New Round of Financing, Total E-Series Funding Nearly 800 Million Yuan

On January 8, 2025, Shanghai Fourier Intelligence Co., Ltd. announced the completion of a new round of financing, with the total amount of Series E funding reaching nearly 800 million yuan. This round of financing was jointly participated by Guoxin Investment, Pudong Venture Capital, Zhangjiang Science & Technology Investment, Zhangke Yaokun Fund, Prosperity7, and Junshan Capital, injecting strong momentum into Fourier's continuous innovation in the robotics field. This also marks another upgrade in Fourier’s strategic layout, further demonstrating the capital market's confidence and support in the company's ongoing growth.

On January 8, 2025, small molecule drug developer Tenvie Therapeutics secured $200 million in financing. The round was led by ARCH Venture Partners, F-Prime Capital, and Mubadala Capital, with participation from other high-quality investors, which will accelerate Tenvie's growth into a multi-clinical asset company. Tenvie Therapeutics is a biotech company dedicated to designing small molecules that transform the treatment of neurological disorders. The company’s foundation is purpose-built, with a diversified portfolio of small molecule products and an experienced CNS drug development team to rapidly deliver multiple clinical assets.

On January 7, 2025, Aviceda Therapeutics, a developer of treatments for immune-mediated diseases, raised $207.5 million in a Series C financing round. The round was co-led by Omega Funds and TCGX, with participation from Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc., and Digitalis Ventures. Leerink Partners served as the financial advisor to Aviceda. The proceeds will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trials of AVD-104 for the treatment of geographic atrophy (GA), a vision-threatening condition secondary to advanced age-related macular degeneration, as well as expansion into other ophthalmic indications.。

Evergreen Nephrology Secures $130 Million to Expand Its Care Model to More Kidney Disease Patients

On January 7, 2025, Evergreen Nephrology, a provider of care services for kidney disease patients, secured $130 million in funding led by Rubicon Founders, Oak HC/FT, and a group of existing investors, with participation from K2 HealthVentures. The funds will drive Evergreen's expansion into new regions while implementing advanced technologies to improve clinical outcomes, streamline care delivery, and reduce the administrative burden on nephrologists, thereby accelerating its growth.。

Fire1, a developer of medical remote monitoring devices, has completed a $120 million financing round to accelerate the development of its heart failure management system.

On January 7, 2025, Fire1, a developer of medical remote monitoring devices, announced the completion of a $120 million financing round led by Polaris Partners and Elevage Medical Technologies. New investors Sands Capital and Longitude Capital also participated in the investment. Existing investors Andera Partners, Gilde Healthcare, Gimv, Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, NEA (New Enterprise Associates), Novo Holdings, and Seventure Partners joined as well. The funds from this round will accelerate the development of its heart failure management system.

Insulin Delivery Device Developer CeQur Raises $120 Million to Support Insulin Delivery Technology

On January 7, 2025, CeQur, a developer of insulin delivery devices, completed a $120 million financing round. The company, headquartered in Horw, Switzerland, plans to use the funds to drive growth and accelerate commercial expansion efforts. It aims to expand its commercial team and outreach programs, bringing its four-day wearable insulin delivery device, Simplicity, to more healthcare providers and people with diabetes.

Health Tech Investment Firm HPCM Announces $150 Million Major Venture Investment in Patho Care

On January 1, 2025, Hamershlag Private Capital Management Limited, a leading health technology investment firm, announced a significant venture capital investment in Patho Care, LLC. Valued at $150.15 million, the transaction aims to acquire and recapitalize through newly issued common stock and cash via the newly established entity, PathoCare Holdings, Inc., to streamline the investment and operational framework. This strategic investment reflects HPCM's commitment to advancing innovative healthcare solutions while delivering substantial returns for its investors. The terms of the deal are designed to ensure that Patho Care, LLC has the resources to expand its operations and solidify its market position.

The above is the monthly report summary, and the table of contents for more monthly report content is as follows:

Global Biomedical Investment and Financing in January 2025

Global Medical Device Investment and Financing in January 2025

Global Digital Health Investment and Financing in January 2025

Global Healthcare Investment and Financing in January 2025

Global Pharmaceutical Business Investment and Financing in January 2025

Welcome ImmediatelyScan the QR code to add the assistantObtainCompleteMonthly ReportAndApply for a Free Trial Database, if added, please inquire proactively: